Isotype selection for antibody-based cancer therapy.
Fc tail
cancer
effector functions
isotype
mAbs
Journal
Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
02
08
2020
revised:
16
10
2020
accepted:
29
10
2020
pubmed:
7
11
2020
medline:
28
9
2021
entrez:
6
11
2020
Statut:
ppublish
Résumé
The clinical application of monoclonal antibodies (mAbs) has revolutionized the field of cancer therapy, as it has enabled the successful treatment of previously untreatable types of cancer. Different mechanisms play a role in the anti-tumour effect of mAbs. These include blocking of tumour-specific growth factor receptors or of immune modulatory molecules as well as complement and cell-mediated tumour cell lysis. Thus, for many mAbs, Fc-mediated effector functions critically contribute to the efficacy of treatment. As immunoglobulin (Ig) isotypes differ in their ability to bind to Fc receptors on immune cells as well as in their ability to activate complement, they differ in the immune responses they activate. Therefore, the choice of antibody isotype for therapeutic mAbs is dictated by its intended mechanism of action. Considering that clinical efficacy of many mAbs is currently achieved only in subsets of patients, optimal isotype selection and Fc optimization during antibody development may represent an important step towards improved patient outcome. Here, we discuss the current knowledge of the therapeutic effector functions of different isotypes and Fc-engineering strategies to improve mAbs application.
Identifiants
pubmed: 33155272
doi: 10.1111/cei.13545
pmc: PMC7874837
doi:
Substances chimiques
Antibodies, Monoclonal
0
Immunoglobulin A
0
Immunoglobulin D
0
Immunoglobulin G
0
Immunoglobulin Isotypes
0
Immunoglobulin M
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
351-365Subventions
Organisme : European Commission
ID : Marie Skłodowska-Curie grant agreement No 765394.
Informations de copyright
© 2020 British Society for Immunology.
Références
J Immunol. 2012 Nov 15;189(10):4981-8
pubmed: 23053513
Immunol Rev. 2015 Nov;268(1):25-51
pubmed: 26497511
Front Immunol. 2019 Jul 10;10:1540
pubmed: 31354709
Haematologica. 2012 Nov;97(11):1686-94
pubmed: 22689689
J Pharm Sci. 2020 Jan;109(1):74-103
pubmed: 31173761
Immunol Cell Biol. 2020 Apr;98(4):305-317
pubmed: 32142167
Trends Immunol. 2014 Jul;35(7):290-8
pubmed: 24953012
Immunol Res. 2014 Aug;59(1-3):203-10
pubmed: 24906530
Front Immunol. 2019 Apr 11;10:704
pubmed: 31031746
Cancer Immunol Res. 2013 Jul;1(1):32-42
pubmed: 24777248
MAbs. 2016;8(1):87-98
pubmed: 26466856
BMC Cancer. 2013 Apr 17;13:195
pubmed: 23594731
Cancer Res. 2017 Mar 1;77(5):1127-1141
pubmed: 28096174
PLoS Biol. 2016 Jan 06;14(1):e1002344
pubmed: 26736041
Science. 2014 Mar 14;343(6176):1260-3
pubmed: 24626930
Trends Biotechnol. 2019 Jan;37(1):9-16
pubmed: 29945725
Nat Commun. 2020 Jan 8;11(1):120
pubmed: 31913287
MAbs. 2020 Jan-Dec;12(1):1685349
pubmed: 31769737
Allergy. 2018 Dec;73(12):2328-2341
pubmed: 29654623
Cancer Cell. 2018 Apr 9;33(4):649-663.e4
pubmed: 29576375
Cancer Immunol Immunother. 2012 Jul;61(7):991-1003
pubmed: 22127364
Immunity. 1994 Aug;1(5):405-13
pubmed: 7882171
Clin Exp Allergy. 2013 Oct;43(10):1110-23
pubmed: 24074329
Int J Cancer. 2019 Jan 15;144(2):345-354
pubmed: 30259976
J Exp Med. 2013 Aug 26;210(9):1685-93
pubmed: 23897982
Protein Sci. 2014 Apr;23(4):378-86
pubmed: 24407959
Blood. 1999 Jun 15;93(12):4387-94
pubmed: 10361137
Front Oncol. 2020 Jan 22;9:1380
pubmed: 32038992
Cancer Cell. 2015 Jan 12;27(1):138-48
pubmed: 25500122
Front Immunol. 2019 Jan 30;9:3124
pubmed: 30761158
J Immunol. 2016 Jul 1;197(1):179-87
pubmed: 27217585
Trends Mol Med. 2020 Jun;26(6):615-626
pubmed: 32470387
Hum Antibodies. 2017;25(3-4):87-109
pubmed: 28085016
MAbs. 2015;7(4):743-51
pubmed: 25970007
Blood. 2018 Jan 4;131(1):49-57
pubmed: 29118009
Blood. 2016 Mar 3;127(9):1097-101
pubmed: 26764357
Immunity. 2018 Nov 20;49(5):958-970.e7
pubmed: 30446386
J Immunol. 2011 Aug 15;187(4):1754-63
pubmed: 21742972
Nat Commun. 2011 Dec 20;2:599
pubmed: 22186895
Clin Cancer Res. 2016 Sep 1;22(17):4341-9
pubmed: 27029491
Cell. 2015 May 21;161(5):1035-1045
pubmed: 25976835
Immunol Cell Biol. 2014 Jul;92(6):475-80
pubmed: 24732076
Front Immunol. 2018 Nov 13;9:2607
pubmed: 30483265
Cell Rep. 2015 Mar 10;10(9):1487-1495
pubmed: 25753415
Cancer Cell. 2020 Jun 8;37(6):850-866.e7
pubmed: 32442402
J Biol Chem. 2017 Mar 3;292(9):3900-3908
pubmed: 28077575
Cancer Immunol Immunother. 2012 Sep;61(9):1535-46
pubmed: 22193986
Annu Rev Immunol. 2016 May 20;34:539-73
pubmed: 26927206
Cancer Cell. 2018 Apr 9;33(4):664-675.e4
pubmed: 29576376
Science. 2005 Dec 2;310(5753):1510-2
pubmed: 16322460
J Immunol. 2017 Jun 1;198(11):4235-4243
pubmed: 28432146
Cancer Cell. 2016 Jun 13;29(6):820-831
pubmed: 27265505
Eur J Clin Invest. 2018 Nov;48 Suppl 2:e12962
pubmed: 29855035
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19501-6
pubmed: 24218606
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
Allergy. 2017 Jun;72(6):866-887
pubmed: 28032353
MAbs. 2018 Jul;10(5):693-711
pubmed: 29733746
J Exp Med. 1987 Nov 1;166(5):1351-61
pubmed: 3500259
J Allergy Clin Immunol Pract. 2020 Jan;8(1):413-415
pubmed: 31295561
Science. 2011 Aug 19;333(6045):1030-4
pubmed: 21852502
Immunity. 2017 Aug 15;47(2):224-233
pubmed: 28813656
Nat Commun. 2018 Nov 15;9(1):4809
pubmed: 30442944
Nat Rev Drug Discov. 2012 Mar 30;11(4):311-31
pubmed: 22460124
Immunol Rev. 2015 Nov;268(1):123-38
pubmed: 26497517
Cancer Immunol Immunother. 2010 Dec;59(12):1791-800
pubmed: 20714721
J Immunol. 2007 Sep 1;179(5):2832-43
pubmed: 17709497
Cancer Cell. 2015 Sep 14;28(3):285-95
pubmed: 26373277
Cancer Res. 2010 Jun 1;70(11):4481-9
pubmed: 20484044
Front Immunol. 2019 Jun 07;10:1296
pubmed: 31231397
Cell Death Differ. 2015 Nov;22(11):1727-41
pubmed: 26292758
EMBO Mol Med. 2013 Aug;5(8):1213-26
pubmed: 23918228
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981
MAbs. 2014 Jan-Feb;6(1):54-72
pubmed: 24423620
Immunity. 2006 Jan;24(1):19-28
pubmed: 16413920
Eur J Immunol. 2003 Apr;33(4):1030-40
pubmed: 12672069
Clin Rev Allergy Immunol. 2020 Apr;58(2):155-171
pubmed: 31144209
J Immunother. 2018 Nov/Dec;41(9):385-398
pubmed: 30273198
DNA Cell Biol. 2014 Sep;33(9):616-23
pubmed: 25050883
PLoS One. 2013 May 07;8(5):e63414
pubmed: 23667612
Front Immunol. 2019 Oct 15;10:2061
pubmed: 31681256
MAbs. 2010 Mar-Apr;2(2):181-9
pubmed: 20150767
Chem Biol. 2014 Dec 18;21(12):1603-9
pubmed: 25500223
Mol Immunol. 2015 Nov;68(1):35-9
pubmed: 26597204
J Biol Chem. 2002 Jul 26;277(30):26733-40
pubmed: 11986321
Front Oncol. 2018 Sep 19;8:387
pubmed: 30298117
Eur J Immunol. 1999 Nov;29(11):3527-37
pubmed: 10556807
Leukemia. 2015 Jul;29(7):1602-4
pubmed: 25634683
Immunol Res. 2007;39(1-3):271-8
pubmed: 17917071
Biochemistry. 2008 Jul 15;47(28):7496-508
pubmed: 18549248
J Immunol. 2003 Aug 1;171(3):1581-7
pubmed: 12874252
J Clin Oncol. 2015 Oct 20;33(30):3467-74
pubmed: 26282650
J Hematol Oncol. 2013 Jan 04;6:1
pubmed: 23286345
Front Immunol. 2018 Jun 07;9:1302
pubmed: 29951057
Immunol Cell Biol. 2020 Apr;98(4):287-304
pubmed: 32157732
Cancer Cell. 2011 Jan 18;19(1):101-13
pubmed: 21251615
Cancer Res. 2008 May 15;68(10):3863-72
pubmed: 18483271
Cancer Res. 2016 Jan 15;76(2):403-17
pubmed: 26634925
Breast Cancer Res. 2011;13(6):R123
pubmed: 22129105
Blood. 1997 Dec 1;90(11):4485-92
pubmed: 9373259
Oncotarget. 2016 Nov 8;7(45):74203-74216
pubmed: 27716623
Mol Cancer Ther. 2019 Jan;18(1):75-88
pubmed: 30282813
Blood. 2009 Apr 16;113(16):3716-25
pubmed: 19018092
MAbs. 2012 Jul-Aug;4(4):419-25
pubmed: 22699226